ReviewAdvanced healthcare materials2025
β-1,3 Glucan Microparticles & Nanoparticles: Fabrication Methods & Applications in Immunomodulation & Targeted Drug Delivery.
Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Optimisation of verapamil hydrochloride loaded polyhydroxyalkanoate nano and microparticles using response surface methodology.Scientific reports · 2026Article
- Glucan-Based Nanoparticles Empower Precision Cancer Immunotherapy: Design Strategies, Immune Reprogramming Mechanisms, and Clinical Translation Prospects.International journal of nanomedicine · 2026Review
- Biogenic synthesis of zinc oxide nanoparticles usingBiotechnology notes (Amsterdam, Netherlands) · 2026Article
- β-1,3 Glucan Microparticles & Nanoparticles: Fabrication Methods & Applications in Immunomodulation & Targeted Drug Delivery.Advanced healthcare materials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Innate immune cells such as macrophages and dendritic cells play major roles in the progression of many cancerous, fibrotic, and autoimmune diseases, often due to environmental cues that skew these cells toward a phenotype that progresses or exacerbates the disease state. As such, a growing focus in treating such diseases is placed on exploiting the high plasticity of these cells to modify or reverse their pro-disease phenotypes using immunomodulatory materials. β-1,3 glucans are one such type of material that has exhibited diverse immunomodulatory effects on immune cells, including the mitigation or reversal of the adverse effects of dysregulated immune cells. In this review, we outline various fabrication techniques to produce β-1,3 glucan-derived microparticles and nanoparticles and discuss the diverse particle properties that can be obtained by tuning glucan chemistry, fabrication method, and formulation components. Furthermore, the immunomodulatory applications of β-1,3 glucan particles are highlighted with a focus on immune cell targeting, modulation, and the delivery of small molecule and macromolecular therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.